ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using ...
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR ...
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with ...
The Beijing-based biotechnology company CorreGene was co-founded by Peking University alumni in 2016 to develop innovative T-cell receptor (TCR) therapies. CorreGene’s T-cell engager (TCE) pipeline ...
The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell ...
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted ...
The MarketWatch News Department was not involved in the creation of this content. Oxford, UK -- March 17, 2026. Enara Bio, a pioneer in Dark Antigen(R) discovery and bispecific T cell engager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results